Inogen Inc (INGN) Director Sells $184,880.00 in Stock

Inogen Inc (NASDAQ:INGN) Director Ray Benjamin M. Anderson sold 1,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $184.88, for a total value of $184,880.00. Following the completion of the transaction, the director now owns 1,989 shares in the company, valued at $367,726.32. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Inogen opened at $193.65 on Friday, according to MarketBeat. Inogen Inc has a 12-month low of $89.01 and a 12-month high of $194.23. The stock has a market capitalization of $4.01 billion, a PE ratio of 126.07, a PEG ratio of 4.76 and a beta of 1.11.

Get Inogen alerts:

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Monday, April 30th. The medical technology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.19. Inogen had a return on equity of 14.81% and a net margin of 9.36%. The firm had revenue of $79.05 million during the quarter, compared to analysts’ expectations of $63.86 million. During the same period in the prior year, the business earned $0.27 EPS. The company’s revenue for the quarter was up 50.6% compared to the same quarter last year. research analysts anticipate that Inogen Inc will post 1.77 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in shares of Inogen by 4.7% in the 1st quarter. Principal Financial Group Inc. now owns 146,433 shares of the medical technology company’s stock worth $17,988,000 after purchasing an additional 6,622 shares in the last quarter. Xact Kapitalforvaltning AB purchased a new position in shares of Inogen in the 1st quarter worth about $303,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in shares of Inogen in the 1st quarter worth about $1,388,000. Highbridge Capital Management LLC purchased a new position in shares of Inogen in the 1st quarter worth about $217,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Inogen in the 1st quarter worth about $486,000. Hedge funds and other institutional investors own 97.86% of the company’s stock.

A number of brokerages have weighed in on INGN. KeyCorp began coverage on Inogen in a research note on Wednesday, June 6th. They issued an “equal weight” rating on the stock. Zacks Investment Research lowered Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Needham & Company LLC restated a “buy” rating on shares of Inogen in a research note on Wednesday, June 13th. ValuEngine upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, JPMorgan Chase & Co. upped their target price on Inogen from $150.00 to $180.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 1st. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $193.80.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Leave a Reply

Your email address will not be published. Required fields are marked *